Contact
Please use this form to send email to PR contact of this press release:
NASDAQ: COEP Collaborates with the University of Pittsburgh Targeting HER2-Positive Cancers. $COEP; Illegally Short Sold
TO:
Coeptis Therapeutics Holdings, Inc.
Dave Mehalick, President and CEO
+1 724-934-6467